The new treatment from Seres Therapeutics provides a simpler, rigorously tested version of stool-based procedures that some medical specialists have used for more than a decade to help patients.The Food and Drug Administration cleared the capsules for adults 18 and older who face risks from repeat infections with Clostridium difficile, a bacteria that can cause severe nausea, cramping and diarrhea.C.
Majdi Osman, the group's medical chief.OpenBiome's standard stool treatment costs less than $1,700 and is typically delivered as a frozen solution within days of ordering. Seres did not disclose the price it will charge for its capsules in a statement Wednesday evening.'We want to make the commercial experience for physicians and patients as easy as possible,' said Eric Shaff, the company's chief executive officer, in an interview ahead of the announcement.